Adult Vaccines Market, Company Adult Vaccines Sales, Country Adult Vaccines - Worldwide Analysis

Description: World Adult Vaccines Market – Market Overview

For much of the 20th century, vaccines were a pharmaceutical success story largely associated with children. Aggressive immunization programs eradicated Polio and Smallpox among developed nations and nearly eliminated Mumps, Pertussis, Measles, and other diseases. While Pediatric Vaccines are an important market, it is now adults who are fueling growth of vaccine products. The world adult vaccines market is expected to nearly double by 2020 from the current figure of 2012.

Vaccination has played an enormous role in the prevention of disease, having had the greatest impact on human health of any medical intervention. As a result, vaccine preventable diseases and their resulting deaths are now rare in the developed world. However, the developing nations have not benefited as much from the introduction of vaccines. Additionally, other issues such as vaccine safety, shortages and bioterrorism continue to weigh upon the industry.

The research study titled “Adult Vaccines Market, Company Adult Vaccines Sales, Country Adult Vaccines - Worldwide Analysis” provides a comprehensive assessment of the fast-evolving, high-growth of World Adult Vaccines Landscape. This 222 page report with 142 Figures and 15 Tables studies: 9 Adult Vaccines Market, 5 Companies Adult Vaccines Sales. In total 28 Adult Vaccines have been researched for this report. This report is divided into 11 chapters.

Adult Vaccines Market & Forecast data (2007 – 2020) covered in the report are as follows:

1. Influenza
2. Cervical Cancer/ HPV
3. Hepatitis
4. Zoster Shingles
5. Pneumococcal
6. Measles, Mumps, Rubella and Varicella (MMRV)
7. Meningococcal
8. Diphtheria, Tetanus, Pertussis (DTP)
9. Travel and Miscellaneous

Companies' Adult Vaccines Sales Share and Forecast data (2007 – 2020) covered in the report

1. GlaxoSmithKline (GSK)
2. Sanofi Pasteur
3. Merck
4. Novartis
5. Pfizer
6. Others

(Chapter 1): Executive Summary

(Chapter 2): This Chapter is divided into 2 parts
A. Adult Vaccines Market and Forecast data from 2007 to 2020
B. Adult Vaccinated Number and Forecast from 2007 to 2020

(Chapter 3): This chapter is divided into 3 parts
A. Provides market share (percentage) of Adult Vaccines in the above mentioned vaccines
B. Provides market share (percentage) of Adult Vaccinated in the above mentioned vaccines
C. Provides above mentioned companies market share in Adult vaccines.

(Chapter No. 4): This chapter is divided into 2 parts
A. Companies given above Sales Share (percentage) in Disease Wise Break up & Forecast
B. Adult Vaccines given above Companies Share and Forecast

(Chapter 5): This chapter talks about all the 9 Adult Vaccines mentioned above. All these vaccines have been further sub-divided into 4 parts
A. Adult Vaccine Market & Forecast
B. Number of Adults Being Vaccinated & Forecast
C. Number of Adult Vaccines Doses & Forecast
D. Number of Cases

(Chapter 6): This chapter studies mentioned above all the 5 companies Adult Vaccines Sales and Forecast. The chapter further talks about the Company alliances with other Companies in order to increase their vaccine sales.

(Chapter 7): This chapter studies mentioned above all the 5 companies’ Sales and Forecast Disease Wise

(Chapter 8): This chapter provides Adult Vaccines Market and Forecast data of 8 Geographic Regions Worldwide.
1. United States
2. North America/Caribbean
3. South America
4. Europe
5. Japan
6. India
7. China
8. Rest of the World (ROW)

(Chapter 9): This chapter comprises of important Mergers and Acquisitions happening in the field of vaccines

(Chapter 10): This chapter studies growth Factors Driving the Adult Vaccines Market. In total 8 growth topics have been discussed in this chapter.

(Chapter 11): This chapter studies Challenges/Hindrances faced by Adult Vaccines Market. In total 7 challenges topics have been discussed in this chapter

Data Sources
This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by a team of industry experts.

Primary sources include industry surveys and telephone interviews with industry experts.

Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Government Agencies, Magazines, Newspapers, Trade associations, Books, Industry Portals, Industry Associations and access to more than 500 paid databases.

Contents:
1. Executive Summary
2.1 World Adult Vaccine – Market & Forecast
2.2 World Adult Vaccine – Number of Adults Being Vaccinated & Forecast

3.2 Disease Wise – Percentage of Adults Being Vaccinated Share & Forecast (2010 – 2020)
3.3 Company Wise – Market Share & Forecast (2010 – 2020)

4.1 Companies Adult Vaccine Sales – Disease Wise Break up Share & Forecast (2010 – 2020)
4.1.1 GlaxoSmithKline (GSK) - Adult Vaccines Sales Share & Forecast
4.1.2 Sanofi Pasteur - Adult Vaccines Sales Share & Forecast
4.1.3 Merck - Adult Vaccines Sales Share & Forecast
4.1.4 Novartis - Adult Vaccines Sales Share & Forecast

4.2 Adult Vaccine Disease Wise Market Break up - Company Share & Forecast (2010 – 2020)
4.2.1 Influenza Adult Vaccines – Company Market Share
4.2.2 Cervical Cancer/HPV Adult Vaccines – Company Market Share
4.2.3 Hepatitis Adult Vaccines – Company Market Share & Forecast
4.2.4 Pneumococcal Adult Vaccines – Company Market Share & Forecast
4.2.5 Meningococcal Adult Vaccines – Company Market Share & Forecast
4.2.6 DTP (Diphtheria, Tetanus, Pertussis) Adult Vaccines – Company Market Share & Forecast

5. World Adult Vaccine Market – Disease Wise Segmentation Analysis
5.1 Influenza Adult Vaccine Analysis & Forecast (2007 – 2020)
5.1.1 Influenza – Adult Vaccine Market & Forecast
5.1.2 Influenza – Number of Adults Being Vaccinated & Forecast
5.1.3 Influenza – Number of Vaccines Doses & Forecast

5.2 Cervical Cancer/ HPV Analysis (2007 – 2020)
5.2.1 Cervical Cancer/ HPV – Adult Vaccine Market & Forecast
5.2.2 Cervical Cancer/ HPV – Number of Adults Being Vaccinated & Forecast
5.2.3 Cervical Cancer/ HPV – Number of Vaccines Doses & Forecast
5.2.4 Cervical Cancer/HPV - Number of New Cases & Forecast

5.3 Zoster Shingles – Adult Vaccine Analysis (2006 – 2020)
5.3.1 Zoster Shingles – Adult Vaccine Market & Forecast
5.3.2 Zoster Shingles – Number of Adults Being Vaccinated & Forecast
5.3.3 Zoster Shingles – Number of Vaccine Doses & Forecast

5.4 Pneumococcal – Adult Vaccine Analysis (2010 – 2020)
5.4.1 Pneumococcal – Adult Vaccine Market & Forecast
5.4.2 Pneumococcal – Number of Adults Being Vaccinated & Forecast
5.4.3 Pneumococcal – Number of Vaccine Doses & Forecast

5.5 Meningococcal – Adult Vaccine Analysis
5.5.1 Meningococcal – Adult Vaccine Market & Forecast
5.5.2 Meningococcal – Number of Adults Being Vaccinated & Forecast
5.5.3 Meningococcal – Number of Vaccines Doses & Forecast

5.6 Measles, Mumps, Rubella and Varicella (MMRV) – Adult Vaccine Analysis
5.6.1 Measles, Mumps, Rubella and Varicella (MMRV) – Adult Vaccine Market & Forecast
5.6.2 Measles, Mumps, Rubella and Varicella (MMRV) – Number of Adults Being Vaccinated & Forecast
5.6.3 Measles, Mumps, Rubella and Varicella (MMRV) – Number of Vaccines Doses & Forecast
5.6.4 MMR - Number of New Cases & Forecast

5.7 Hepatitis – Adult Vaccine Market Analysis
5.7.1 Hepatitis – Adult Vaccine Market & Forecast
5.7.2 Hepatitis – Number of Adults Being Vaccinated & Forecast
5.7.3 Hepatitis – Number of Vaccine Doses & Forecast
5.7.4 Hepatitis – Number of Acute (New) Cases

5.8 Diphtheria, Tetanus, Pertussis (DTP) – Adult Vaccine Market Analysis
5.8.1 DTP (Diphtheria, Tetanus, Pertussis) – Adult Vaccine Market & Forecast
5.8.2 Diphtheria, Tetanus, Pertussis (DTP) – Number of Adults Being Vaccinated & Forecast
5.8.3 DTP - Number of Vaccines Doses & Forecast
5.8.4 Diphtheria, Tetanus & Pertussis (DTP) - Number of Cases

5.9 Travel and Miscellaneous – Adult Vaccine Market

6. World Adult Vaccine Market – Company Analysis & Strategic Alliances
6.1 GlaxoSmithKline
   6.1.1 GlaxoSmithKline (GSK) - Adult Vaccine Sales & Forecast
   6.1.2 Strategic Alliances of GlaxoSmithKline (GSK)

6.2 Sanofi Pasteur
   6.2.1 Sanofi Pasteur Vaccines Sales Analysis
   6.2.2 Strategic Alliances of Sanofi Pasteur

6.3 Merck
   6.3.1 Merck Vaccines Sales Analysis
   6.3.2 Strategic Alliances of Merck

6.4 Novartis
   6.4.1 Novartis Vaccines Sales Analysis
   6.4.2 Strategic Alliances of Novartis

6.5 Pfizer
   6.5.1 Pfizer Adult Vaccines Sales & Forecast
   6.5.2 Strategic Alliances of Pfizer

6.6 Other Companies

7.1 GlaxoSmithKline (GSK) – Adult Vaccines Sales & Forecast
   7.1.1 GlaxoSmithKline (GSK) – Influenza Adult Vaccines Sales & Forecast
   7.1.2 GlaxoSmithKline (GSK) – Cervical Cancer/HPV Adult Vaccines Sales & Forecast
   7.1.3 GlaxoSmithKline (GSK) – Hepatitis Adult Vaccines Sales & Forecast
   7.1.4 GlaxoSmithKline (GSK) – DTP Adult Vaccines Sales & Forecast

7.2 Sanofi Pasteur – Adult Vaccines Sales & Forecast
   7.2.1 Sanofi Pasteur – Influenza Adult Vaccines Sales & Forecast
   7.2.2 Sanofi Pasteur – DTP Adult Vaccines Sales & Forecast
   7.2.3 Sanofi Pasteur – Meningococcal Adult Vaccines Sales & Forecast

7.3 Merck – Adult Vaccines Sales & Forecast
   7.3.1 Merck – Influenza Adult Vaccines Sales & Forecast
   7.3.2 Merck – Cervical Cancer/HPV Adult Vaccines Sales & Forecast
   7.3.3 Merck – Zoster Shingles Adult Vaccines Sales & Forecast
   7.3.4 Merck – Pneumococcal Adult Vaccines Sales & Forecast
   7.3.5 Merck – MMRV Adult Vaccines Sales & Forecast
   7.3.6 Merck – Hepatitis Adult Vaccines Sales & Forecast

7.4 Novartis – Adult Vaccines Sales & Forecast
   7.4.1 Novartis – Influenza Adult Vaccines Sales & Forecast
   7.4.2 Novartis – Meningococcal Adult Vaccines Sales & Forecast

7.5 Pfizer – Adult Vaccines Sales & Forecast
   7.5.1 Pfizer – Pneumococcal Adult Vaccines Sales & Forecast

8. World Adult Vaccine Market – Geographical Distribution
8.1 United States – Adult Vaccine Market & Forecast
8.2 North America/Caribbean – Adult Vaccine Market & Forecast
8.3 South America – Adult Vaccine Market & Forecast
8.4 Europe – Adult Vaccine Market & Forecast
8.5 Japan – Adult Vaccine Market & Forecast
8.6 India – Adult Vaccine Market & Forecast
8.7 China – Adult Vaccine Market & Forecast
8.8 Rest of the World (ROW) – Adult Vaccine Market & Forecast


10. Growth Factors for Adult Vaccines
10.1 Global Immunization Vision and Strategy (GIVS)
10.2 GAVI Model Fuelling Vaccine Manufacturers
10.2.1 The Partnership Model
10.2.2 The Business Model

10.3 Increasing Vaccine Availability in United States
10.4 The Vaccine Safety Data link Project
10.5 The Vaccine Injury Compensation Program
10.6 Transforming of Vaccine Technologies
10.7 Global Vaccine Action Plan by WHO (2011 - 2020)
10.8 Continuous Focus on Effective Communication Strategies

11. Challenges for Adult Vaccines Market
11.1 Hurdles to Optimal use of Licensed Vaccines
11.1.1 Technical Obstacles
11.1.2 Economic obstacles
11.1.3 Cultural Obstacles

11.2 Complexity of Vaccine Development & Approval System Thwarts Product Development
11.2.1 Legal Obstacles
11.2.2 General Technical Barriers
11.2.3 Economic Barriers
11.2.4 Regulatory Barriers

11.3 Shortening the Timeline for Vaccine Development

11.4 Refusal/Resistance to Vaccination
11.4.1 Vaccine Adverse Event Reporting System

11.5 Vaccine Shortages and Delays

11.6 Obstacles in Vaccine Research & Development

11.7 Barriers to New Entrants in the Vaccines Market

List of Figures:

Figure 2 1: Worldwide – Adult Vaccine Market (Million US$), 2007 – 2012
Figure 2 2: Worldwide – Forecast for Adult Vaccine Market (Million US$), 2013 – 2020
Figure 2 3: Worldwide – Number of Adults Being Vaccinated with Adult Vaccines (Million), 2007 – 2012
Figure 2 4: Worldwide – Forecast for Number of Adults Being Vaccinated with Adult Vaccines (Million), 2013 – 2020

Figure 3 1: Worldwide – Diseases Wise Adult Vaccine Market Share (Percent), 2010 – 2012
Figure 3 2: Worldwide – Forecast for Diseases Wise Adult Vaccine Market Share (Percent), 2013 – 2020
Figure 3 3: Worldwide – Company Wise Adult Vaccine Market Share (Percent), 2010 – 2012
Figure 3 4: Worldwide – Forecast for Company Wise Adult Vaccine Market Share (Percent), 2013 – 2020

Figure 4 1: Worldwide – GSK Adult Vaccine Sales Share (Percent), 2007 – 2012
Figure 5.35: Worldwide – Number of MMRV Vaccines Doses (Million), 2007 – 2012
Figure 5.36: Worldwide – Forecast for Number of MMRV Vaccines Doses (Million), 2013 – 2020
Figure 5.37: Worldwide – Hepatitis Adult Vaccine Market (Million US$), 2007 – 2012
Figure 5.38: Worldwide – Forecast for Hepatitis Adult Vaccine Market (Million US$), 2013 – 2020
Figure 5.39: Worldwide – Number of Adults Being Vaccinated with Hepatitis Vaccines (Million), 2007 – 2012
Figure 5.40: Worldwide – Forecast for Number of Adults Being Vaccinated with Hepatitis Vaccines (Million), 2013 – 2020
Figure 5.41: Worldwide – Number of Hepatitis Vaccines Doses (Million), 2007 – 2012
Figure 5.42: Worldwide – Forecast for Number of Hepatitis Vaccines Doses (Million), 2013 – 2020
Figure 5.43: United States – Reported Acute (New) Cases of Hepatitis A Virus (Number), 2005 – 2011
Figure 5.44: United States – Reported Acute (New) Cases of Hepatitis B Virus (Number), 2005 – 2011
Figure 5.45: Worldwide – DTP Adult Vaccine Market (Million US$), 2010 – 2012
Figure 5.46: Worldwide – Forecast for DTP Adult Vaccine Market (Million US$), 2013 – 2020
Figure 5.47: Worldwide – Number of Adults Being Vaccinated with DTP Vaccines (Million), 2010 – 2012
Figure 5.48: Worldwide – Forecast for Number of Adults Being Vaccinated with DTP (Million), 2013 – 2020
Figure 5.49: Worldwide – Number of DTP Vaccine Doses (Million), 2010 – 2012
Figure 5.50: Worldwide – Forecast for Number of DTP Vaccine Doses (Million), 2013 – 2020
Figure 5.51: Worldwide – Travel and Misc. Adult Vaccine Market (Million US$), 2007 – 2012
Figure 5.52: Worldwide – Forecast for Travel and Misc. Adult Vaccine Market (Million US$), 2013 – 2020

Figure 6.1: Worldwide – GlaxoSmithKline Adult Vaccines Sales (Million US$), 2007 – 2012
Figure 6.2: Worldwide – Forecast for GlaxoSmithKline Adult Vaccines Sales (Million US$), 2013 – 2020
Figure 6.3: Worldwide – Sanofi Pasteur Adult Vaccines Sales (Million US$), 2010 – 2012
Figure 6.4: Worldwide – Forecast for Sanofi Pasteur Adult Vaccines Sales (Million US$), 2013 – 2020
Figure 6.5: Worldwide – Merck Adult Vaccines Sales (Million US$), 2007 – 2012
Figure 6.6: Worldwide – Forecast for Merck Adult Vaccines Sales (Million US$), 2013 – 2020
Figure 6.7: Worldwide – Novartis Adult Vaccines Sales (Million US$), 2010 – 2012
Figure 6.8: Worldwide – Forecast for Novartis Adult Vaccines Sales (Million US$), 2013 – 2020
Figure 6.9: Worldwide – Pfizer Adult Vaccines Sales (Million US$), 2010 – 2012
Figure 6.10: Worldwide – Forecast for Pfizer Adult Vaccines Sales (Million US$), 2013 – 2020
Figure 6.11: Worldwide – Other Companies Adult Vaccines Sales (Million US$), 2010 – 2012
Figure 6.12: Worldwide – Forecast for Other Companies Adult Vaccines Sales (Million US$), 2013 – 2020

Figure 7.1: Worldwide – GSK Influenza Adult Vaccines Sales (Million US$), 2007 – 2012
Figure 7.2: Worldwide – Forecast for GSK Influenza Adult Vaccines Sales (Million US$), 2013 – 2020
Figure 7.3: Worldwide – GSK Cervical Cancer/HPV Adult Vaccines Sales (Million US$), 2007 – 2012
Figure 7.4: Worldwide – Forecast for GSK Cervical Cancer/HPV Adult Vaccines Sales (Million US$), 2013 – 2020
Figure 7.5: Worldwide – GSK Hepatitis Adult Vaccines Sales (Million US$), 2007 – 2012
Figure 7.6: Worldwide – Forecast for GSK Hepatitis Adult Vaccines Sales (Million US$), 2013 – 2020
Figure 7.7: Worldwide – GSK DTP Adult Vaccines Sales (Million US$), 2007 – 2012
Figure 7.8: Worldwide – Forecast for GSK DTP Adult Vaccines Sales (Million US$), 2013 – 2020
Figure 7.9: Worldwide – Sanofi Pasteur Influenza Adult Vaccines Sales (Million US$), 2009 – 2012
Figure 7.10: Worldwide – Forecast for Sanofi Pasteur Influenza Adult Vaccines Sales (Million US$), 2013 – 2020
Figure 7.11: Worldwide – Sanofi Pasteur DTP Adult Vaccines Sales (Million US$), 2010 – 2012
Figure 7.12: Worldwide – Forecast for Sanofi Pasteur DTP Adult Vaccines Sales (Million US$), 2013 – 2020
Figure 7.13: Worldwide – Sanofi Pasteur Meningococcal Adult Vaccines Sales (Million US$), 2009 – 2012
Figure 7.14: Worldwide – Forecast for Sanofi Pasteur Meningococcal Adult Vaccines Sales (Million US$), 2013 – 2020
Figure 7.15: Worldwide – Merck Influenza Adult Vaccines Sales (Million US$), 2010 – 2012
Figure 7.16: Worldwide – Forecast for Merck Influenza Adult Vaccines Sales (Million US$), 2013 – 2020
Figure 7.17: Worldwide – Merck Cervical Cancer/HPV Adult Vaccines Sales (Million US$), 2007 – 2012
Figure 7.18: Worldwide – Forecast for Merck Cervical Cancer/HPV Adult Vaccines Sales (Million US$), 2013 – 2020
Figure 7.19: Worldwide – Merck Zoster Shingles Adult Vaccines Sales (Million US$), 2007 – 2012
Figure 7.20: Worldwide – Forecast for Merck Zoster Shingles Adult Vaccines Sales (Million US$), 2013 – 2020
Figure 7.21: Worldwide – Merck Pneumococcal Adult Vaccines Sales (Million US$), 2007 – 2012
Figure 7.22: Worldwide – Forecast for Merck Pneumococcal Adult Vaccines Sales (Million US$), 2013 – 2020
Figure 7.23: Worldwide – Merck MMRV Adult Vaccines Sales (Million US$), 2007 – 2012
Figure 7.24: Worldwide – Forecast for Merck MMRV Adult Vaccines Sales (Million US$), 2013 – 2020
Figure 7.25: Worldwide – Merck Hepatitis Adult Vaccines Sales (Million US$), 2008 – 2012
Figure 7.26: Worldwide – Forecast for Merck Hepatitis Adult Vaccines Sales (Million US$), 2013 – 2020
Figure 7.27: Worldwide – Novartis Influenza Adult Vaccines Sales (Million US$), 2010 – 2012
Figure 7.28: Worldwide – Forecast for Novartis Influenza Adult Vaccines Sales (Million US$), 2013 – 2020
Figure 7.29: Worldwide – Novartis Meningococcal Adult Vaccines Sales (Million US$), 2010 – 2012
Figure 7.30: Worldwide – Forecast for Novartis Meningococcal Adult Vaccines Sales (Million US$), 2013 – 2020
Figure 7.31: Worldwide – Pfizer Pneumococcal Adult Vaccines Sales (Million US$), 2010 – 2012
Figure 7.32: Worldwide – Forecast for Pfizer Pneumococcal Adult Vaccines Sales (Million US$), 2013 – 2020

Figure 8.1: United States – Adult Vaccines Market (Million US$), 2007 – 2012
Figure 8.2: United States – Forecast for Adult Vaccines Market (Million US$), 2013 – 2020
Figure 8.3: North America/Caribbean – Adult Vaccines Market (Million US$), 2007 – 2012
Figure 8.4: North America/Caribbean – Forecast for Adult Vaccines Market (Million US$), 2013 – 2020
Figure 8.5: South America – Adult Vaccines Market (Million US$), 2007 – 2012
Figure 8.6: South America – Forecast for Adult Vaccines Market (Million US$), 2013 – 2020
Figure 8.7: Europe – Adult Vaccines Market (Million US$), 2007 – 2012
Figure 8.8: Europe – Forecast for Adult Vaccines Market (Million US$), 2013 – 2020
Figure 8.9: Japan – Adult Vaccines Market (Million US$), 2007 – 2012
Figure 8.10: Japan – Forecast for Adult Vaccines Market (Million US$), 2013 – 2020
Figure 8.11: India – Adult Vaccines Market (Million US$), 2007 – 2012
Figure 8.12: India – Forecast for Adult Vaccines Market (Million US$), 2013 – 2020
Figure 8.13: China – Adult Vaccines Market (Million US$), 2007 – 2012
Figure 8.14: China – Forecast for Adult Vaccines Market (Million US$), 2013 – 2020
Figure 8.15: ROW – Adult Vaccines Market (Million US$), 2007 – 2012
Figure 8.16: ROW – Forecast for Adult Vaccines Market (Million US$), 2013 – 2020

Figure 10.1: Increasing Number of GAVI Suppliers Based in Emerging Markets, 2001 – 2011
Figure 10.2: US – Number of Retail Clinics offering Vaccination (Number), 2007 – 2012

List of Tables:

Table 3.1: Worldwide – Share of Adults Being Vaccinated with Adult Vaccines (Percent), 2010 – 2012
Table 3.2: Worldwide – Forecast for Share of Adults Being Vaccinated with Adult Vaccines (Percent), 2013 – 2020

Table 5.1: Cervical Cancer – Region Wise Number of New Cancer Cases (Number), 2009 – 2012
Table 5.2: Cervix – Forecast for Region Wise Number of New Cancer Cases (Number), 2013 – 2018
Table 5.3: Worldwide (By Geographic Region) – Number of Measles Cases (Number), 2001 – 2012
Table 5.4: Worldwide (By Geographic Region) – Number of Mumps Cases (Number), 2001 – 2012
Table 5.5: Worldwide (By Geographic Region) – Number of Rubella Cases (Number), 2001 – 2011
Table 5.6: Worldwide (By Geographic Region) – Number of Diphtheria Cases (Number), 2001 – 2012
Table 5.7: Worldwide (By Geographic Region) – Number of nTetanus Cases (Number), 2001 – 2012
Table 5.8: Worldwide (By Geographic Region) – Number of tTetanus Cases (Number), 2001 – 2012
Table 5.9: Worldwide (By Geographic Region) – Number of Pertussis Cases (Number), 2001 – 2012


Table 10.1: Worldwide – Total Future Deaths Averted through Vaccination (Million), 2011 – 2020
Table 10.2: Goal-Level Indicators, 2015 & 2020
Table 10.3: Improvement Strategies or Requirements – the Joint Commission and the Project’s Collaborating Organizations

Ordering:
Order Online - [http://www.researchandmarkets.com/reports/2693683/](http://www.researchandmarkets.com/reports/2693683/)
Order by Fax - using the form below
Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
RESEARCH AND MARKETS   Page 1 of 2

Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit

http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Adult Vaccines Market, Company Adult Vaccines Sales, Country Adult Vaccines - Worldwide Analysis
Web Address: http://www.researchandmarkets.com/reports/2693683/
Office Code: SC6IJJX78

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Product Type</th>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User</td>
<td></td>
<td>USD 1697</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide</td>
<td></td>
<td>USD 2387</td>
</tr>
<tr>
<td>Hard Copy</td>
<td></td>
<td>USD 1910 + USD 57 Shipping/Handling</td>
</tr>
<tr>
<td>CD-ROM</td>
<td></td>
<td>USD 1782 + USD 57 Shipping/Handling</td>
</tr>
</tbody>
</table>

* Shipping/Handling is only charged once per order.*

Contact Information
Please enter all the information below in BLOCK CAPITALS

<table>
<thead>
<tr>
<th>Field</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Title</td>
<td>Mr [ ] Mrs [ ] Dr [ ] Miss [ ] Ms [ ] Prof [ ]</td>
</tr>
<tr>
<td>First Name</td>
<td></td>
</tr>
<tr>
<td>Last Name</td>
<td></td>
</tr>
<tr>
<td>Email Address</td>
<td></td>
</tr>
<tr>
<td>Job Title</td>
<td></td>
</tr>
<tr>
<td>Organisation</td>
<td></td>
</tr>
<tr>
<td>Address</td>
<td></td>
</tr>
<tr>
<td>City</td>
<td></td>
</tr>
<tr>
<td>Postal / Zip Code</td>
<td></td>
</tr>
<tr>
<td>Country</td>
<td></td>
</tr>
<tr>
<td>Phone Number</td>
<td></td>
</tr>
<tr>
<td>Fax Number</td>
<td></td>
</tr>
</tbody>
</table>

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:

<table>
<thead>
<tr>
<th>Account number</th>
<th>833 130 83</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sort code</td>
<td>98-53-30</td>
</tr>
<tr>
<td>Swift code</td>
<td>ULSBIE2D</td>
</tr>
<tr>
<td>IBAN number</td>
<td>IE78ULSB98533083313083</td>
</tr>
<tr>
<td>Bank Address</td>
<td>Ulster Bank, 27-35 Main Street, Blackrock, Co. Dublin, Ireland.</td>
</tr>
</tbody>
</table>

If you have a Marketing Code please enter it below:

Marketing Code: ________________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:

(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World